OPRA:NASDAQOpera Limited Analysis
Data as of 2026-06-13 - not real-time
$18.18
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Opera Limited (OPRA) is trading at $18.18, comfortably above its 20‑day SMA (18.03) and 50‑day SMA (17.46), indicating a short‑term bullish bias, while still below the 200‑day SMA (15.63) that suggests ample upside potential. The RSI sits at 53, signaling neutral momentum, and the MACD histogram is negative, hinting at a near‑term pullback risk. The stock’s beta of 1.51 and 30‑day volatility of 31.8% point to a high‑risk profile, yet the recent Extreme Greed market sentiment (fear‑greed index 89.86) may be inflating short‑term demand. Fundamentally, OPRA trades at a forward PE of 10.4 versus an industry average of 16.98, and the DCF‑derived fair value of $50.08 implies a 44.6% upside. A dividend yield of 4.4% with a payout ratio around 63%, supported by solid operating cash flow and a modest debt load, underscores dividend sustainability. The recent announcement of a $0.40 cash dividend reinforces the commitment to shareholder returns. Overall, the combination of undervaluation, strong cash generation, and a strategic focus on AI‑enhanced browsers suggests a compelling long‑term case, while the technical setup warrants cautious positioning in the near term.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above 20‑day and 50‑day SMAs indicating short‑term strength
- Negative MACD histogram suggesting possible near‑term pullback
- Stable volume and support level at $16.73 providing downside protection
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value $50.08 implies ~45% upside
- Forward PE of 10.4 well below industry average
- Attractive 4.4% dividend yield with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong revenue growth (23% YoY) and healthy operating margins
- Strategic AI and Web3 initiatives expanding future growth avenues
- Robust cash generation and low debt supporting long‑term financial health
Key Metrics & Analysis
Financial Health
Revenue Growth23.20%
Profit Margin17.71%
P/E Ratio14.4
ROE11.97%
ROA5.76%
Debt/Equity0.90
P/B Ratio1.7
Op. Cash Flow$143.9M
Free Cash Flow$128.4M
Industry P/E17.0
Technical Analysis
TrendBullish
RSI53.1
Support$16.73
Resistance$19.38
MA 20$18.03
MA 50$17.46
MA 200$15.63
MACDBearish
VolumeStable
Fear & Greed Index89.86
Valuation
Fair Value$50.08
Target Price$26.29
Upside/Downside44.59%
GradeUndervalued
TypeBlend
Dividend Yield4.40%
Risk Assessment
Beta1.51
Volatility31.84%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.